With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure.
After Abogen Biosciences’ COVID shot missed the commercial window, the big question was whether its mRNA technology could create value beyond vaccines. Novartis’ $575 million upfront commitment is the clearest external validation yet of that broader therapeutic potential.
The Regional Leader acquired Stolberg & Blanchette, expanding its New England footprint, adding business valuation expertise and strengthening the firm’s existing industry specialties.
Executives are dealing with more business risks as the impact of artificial intelligence cascades across the economy and brings challenges and opportunities.
The former head of the Institute of Internal Auditors, Richard Chambers, has penned his fifth book, ‘Trusted Advisors: The Human Edge in the World of AI.’